World Hepatitis Day 2026: Breaking Down Barriers with Rapid Diagnostics
On World Hepatitis Day 2026,
Microprofit Biotech stands with the World Health Organization (WHO) and the global health community under this year's theme: "Hepatitis: Let's Break It Down."
Viral hepatitis remains one of the world's most persistent public health challenges. According to the WHO, an estimated 287 million people were living with chronic hepatitis B or C in 2024, and 1.3 million lives were lost to these preventable diseases in that year alone. Effective vaccines, accurate diagnostics, and curative treatments are already within reach — yet for millions of people, the barriers of distance, cost, and limited healthcare infrastructure keep these tools out of reach.
Turning Minutes into Lifesaving Decisions
At the heart of hepatitis elimination lies a simple but critical variable: time. For a patient in a rural clinic or an under-resourced district hospital, the weeks spent waiting for a centralized laboratory result can mean the difference between early intervention and irreversible liver damage.
This is where point-of-care testing (POCT) and rapid diagnostics transform the equation. By equipping frontline healthcare professionals with fast, accurate, and accessible diagnostic tools, the diagnostic journey can be compressed from weeks to minutes — enabling clinicians to make informed treatment decisions on the spot, without the delay of sample transport, cold chain logistics, or centralized lab dependency.
Microprofit Biotech's Commitment
At Microprofit Biotech, we believe that fast, accurate, and accessible diagnostics should be the standard — not a privilege. Through our fluorecare® brand, we are dedicated to developing and delivering POCT and rapid test solutions that empower healthcare providers to diagnose earlier, treat faster, and bring quality care closer to the communities that need it most.
Breaking down the barriers to hepatitis elimination is not a task for any single organization — it requires sustained collaboration across governments, health systems, industry, and communities. As the WHO's 2026 campaign calls for turning proven science into action through stronger political commitment and expanded equitable access, Microprofit Biotech is proud to contribute by making diagnostics faster, simpler, and more accessible — one test at a time.
Every minute matters. Let's break it down, together.
About Microprofit Biotech
Shenzhen Microprofit Biotech Co., Ltd. is a National High-Tech Enterprise and the company behind the fluorecare® brand. With 29 years of industry experience and 99 technical patents, the company specializes in in-vitro diagnostics (IVD), intelligent POCT systems, biological raw materials, and cell science. Through its fluorecare® brand, Microprofit delivers high-quality diagnostic solutions to over 100 countries, supporting decentralized and accessible healthcare worldwide.
For more information, visit www.microprofit-bio.com or contact our international team at info@microprofit-bio.com.
